Sept 25 (Reuters) - 2seventy bio on Wednesday
said it would discontinue enrolling new patients in the
late-stage study for its cell therapy to treat newly diagnosed
myeloma, which is a type of blood cancer.
(Reporting by Kashish Tandon in Bengaluru; Editing by Abinaya
Vijayaraghavan)